Orea-Soufi, A., Castillo-Lluva, S., Salvador-Tormo, N., Martín-Cabrera, P., Recuero, S., Gabicagogeascoa, E., Moreno-Valladares, M., Mendiburu-Eliçabe, M., Blanco-Gómez, A., Ramos-Pittol, J.M., García-Taboada, E., Ocaña, A., Cimas, F.J., Matheu, A., Álvarez-López, I., Velasco, G., Lorente, M.

The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer.

(2021) Cancers, 13 (21), art. no. 5307,

DOI: 10.3390/cancers13215307

RESUMEN

Breast cancer is the most frequent type of cancer in women. More than 70% of these tumors belong to the so-called luminal subtype which has, in general, a good prognosis. However, a fraction of patients with luminal breast cancer progress to an advanced or metastatic disease, which remains a major clinical and social problem. Therefore, it is crucial to identify novel biomarkers that help to predict the progression of the disease and to develop more efficacious therapeutic approaches to fight advanced luminal breast cancer. In this work we found that the increased expression of the protein tribbles pseudokinase 3 (TRIB3) is associated with a good prognosis and a better response to therapy in luminal breast cancer patients. We also found that this effect is at least in part due to the ability of TRIB3 to inhibit the activity of the oncogene HER2.